10 research outputs found
Radiochemistry and In Vivo Imaging of [<sup>45</sup>Ti]Ti-THP-PSMA
Titanium-45 (45Ti) is
a radionuclide with excellent
physical characteristics for use in positron emission tomography (PET)
imaging, including a moderate half-life (3.08 h), decay by positron
emission (85%), and a low mean positron energy of 0.439 MeV. However,
challenges associated with titanium chemistry have led to the underdevelopment
of this radionuclide for incorporation into radiopharmaceuticals.
Expanding on our recent studies, which showed promising results for
the complexation of 45Ti with the tris hydroxypyridinone
(THPMe) chelator, the current work aimed to optimize the
chemistry and imaging attributes of [45Ti]Ti-THP-PSMA as
a new PET radiopharmaceutical. Methods. Radiolabeling
of THP-PSMA was optimized with [45Ti]Ti-citrate at varying
pHs and masses of the precursor. The stability of the radiolabeled
complex was assessed in mouse serum for up to 6 h. The affinity of
[45Ti]Ti-THP-PSMA for prostate-specific membrane antigen
(PSMA) was assessed using LNCaP (PSMA +) and PC3 (PSMA -) cell lines.
In vivo imaging and biodistribution analysis were performed in tumor-bearing
xenograft mouse models to confirm the specificity of the tumor uptake. Results. > 95% of radiolabeling was achieved with a high
specific
activity of 5.6 MBq/nmol under mild conditions. In vitro cell binding
studies showed significant binding of the radiolabeled complex with
the PSMA-expressing LNCaP cell line (11.9 ± 1.5%/mg protein-bound
activity) compared to that with the nonexpressing PC3 cells (1.9 ±
0.4%/mg protein-bound activity). In vivo imaging and biodistribution
studies confirmed specific uptake in LNCaP tumors (1.6 ± 0.27%
ID/g) compared to that in PC3 tumors (0.39 ± 0.2% ID/g). Conclusion. This study showed a simple one-step radiolabeling
method for 45Ti with THP-PSMA under mild conditions (pH
8 and 37 °C). In vitro cell studies showed promise, but in vivo
tumor xenograft studies indicated low tumor uptake. Overall, this
study shows the need for more chelators for 45Ti for the
development of a PET radiopharmaceutical for cancer imaging
Synthesis and antiplasmodial evaluation of 1H-1,2,3-triazole grafted 4-aminoquinoline-benzoxaborole hybrids and benzoxaborole analogues
International audienc
Assessing genetic variation for heat stress tolerance in Indian bread wheat genotypes using morpho-physiological traits and molecular markers
A General Design Strategy Enabling the Synthesis of Hydrolysis-Resistant, Water-Stable Titanium(IV) Complexes
Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals
Three isotopes of scandium43Sc, 44Sc, and 47Schave attracted increasing
attention
as potential candidates for use in imaging and therapy, respectively,
as well as for possible theranostic use as an elementally matched
pair. Here, we present the octadentate chelator 3,4,3-(LI-1,2-HOPO)
(or HOPO), an effective chelator for hard cations, as a potential
ligand for use in radioscandium constructs with simple radiolabeling
under mild conditions. HOPO forms a 1:1 Sc-HOPO complex that was fully
characterized, both experimentally and theoretically. [47Sc]Sc-HOPO exhibited good stability in chemical and biological challenges
over 7 days. In healthy mice, [43,47Sc]Sc-HOPO cleared
the body rapidly with no signs of demetalation. HOPO is a strong candidate
for use in radioscandium-based radiopharmaceuticals
Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals
Three isotopes of scandium43Sc, 44Sc, and 47Schave attracted increasing
attention
as potential candidates for use in imaging and therapy, respectively,
as well as for possible theranostic use as an elementally matched
pair. Here, we present the octadentate chelator 3,4,3-(LI-1,2-HOPO)
(or HOPO), an effective chelator for hard cations, as a potential
ligand for use in radioscandium constructs with simple radiolabeling
under mild conditions. HOPO forms a 1:1 Sc-HOPO complex that was fully
characterized, both experimentally and theoretically. [47Sc]Sc-HOPO exhibited good stability in chemical and biological challenges
over 7 days. In healthy mice, [43,47Sc]Sc-HOPO cleared
the body rapidly with no signs of demetalation. HOPO is a strong candidate
for use in radioscandium-based radiopharmaceuticals
Proceedings of International Conference on Women Researchers in Electronics and Computing
This proceeding contains articles on the various research ideas of the academic community and practitioners presented at the international conference, âWomen Researchers in Electronics and Computingâ (WRECâ2021). WREC'21 was organized in online mode by Dr. B R Ambedkar National Institute of Technology, Jalandhar (Punjab), INDIA during 22 â 24 April 2021. This conference was conceptualized with an objective to encourage and motivate women engineers and scientists to excel in science and technology and to be the role models for young girls to follow in their footsteps. With a view to inspire women engineers, pioneer and successful women achievers in the domains of VLSI design, wireless sensor networks, communication, image/ signal processing, machine learning, and emerging technologies were identified from across the globe and invited to present their work and address the participants in this women oriented conference.
Conference Title: International Conference on Women Researchers in Electronics and ComputingConference Acronym: WREC'21Conference Date: 22â24 April 2021Conference Location:Â Online (Virtual Mode)Conference Organizers: Department of Electronics and Communication Engineering, Dr. B. R. Ambedkar National Institute of Technology, Jalandhar, Punjab, INDI
International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module
âąWe report INICC device-associated module data of 50 countries from 2010-2015.âąWe collected prospective data from 861,284 patients in 703 ICUs for 3,506,562 days.âąDA-HAI rates and bacterial resistance were higher in the INICC ICUs than in CDC-NHSN's.âąDevice utilization ratio in the INICC ICUs was similar to CDC-NHSN's.
Background: We report the results of International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2010-December 2015 in 703 intensive care units (ICUs) in Latin America, Europe, Eastern Mediterranean, Southeast Asia, and Western Pacific.
Methods: During the 6-year study period, using Centers for Disease Control and Prevention National Healthcare Safety Network (CDC-NHSN) definitions for device-associated health care-associated infection (DA-HAI), we collected prospective data from 861,284 patients hospitalized in INICC hospital ICUs for an aggregate of 3,506,562 days.
Results: Although device use in INICC ICUs was similar to that reported from CDC-NHSN ICUs, DA-HAI rates were higher in the INICC ICUs: in the INICC medical-surgical ICUs, the pooled rate of central line-associated bloodstream infection, 4.1 per 1,000 central line-days, was nearly 5-fold higher than the 0.8 per 1,000 central line-days reported from comparable US ICUs, the overall rate of ventilator-associated pneumonia was also higher, 13.1 versus 0.9 per 1,000 ventilator-days, as was the rate of catheter-associated urinary tract infection, 5.07 versus 1.7 per 1,000 catheter-days. From blood cultures samples, frequencies of resistance of Pseudomonas isolates to amikacin (29.87% vs 10%) and to imipenem (44.3% vs 26.1%), and of Klebsiella pneumoniae isolates to ceftazidime (73.2% vs 28.8%) and to imipenem (43.27% vs 12.8%) were also higher in the INICC ICUs compared with CDC-NHSN ICUs.
Conclusions: Although DA-HAIs in INICC ICU patients continue to be higher than the rates reported in CDC-NSHN ICUs representing the developed world, we have observed a significant trend toward the reduction of DA-HAI rates in INICC ICUs as shown in each international report. It is INICC's main goal to continue facilitating education, training, and basic and cost-effective tools and resources, such as standardized forms and an online platform, to tackle this problem effectively and systematically
International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module
We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health careâassociated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396Â days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central lineâassociated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN